Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1902922230
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1220 Blalock Rd, Suite 300
Houston, TX, 77055
Phone (713) 464-3343
Groups this clinician bills Medicare through
Medicare paid, 2024
$49K
3,029 services
Medicare patients, 2024
58
Average age 74
Drug cost, 2024
$8.5M
1,923 prescriptions
Company payments, 2025
$1,491
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Maria A Scouros was code 99214 (office e&m - established), 158 times for 46 patients. In total Maria A Scouros billed 3,029 services in 47 codes, and Medicare paid $49K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-08-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 158 | 46 | $95.40 | $15K |
| 99204 Office E&M - New | Office | 15 | 15 | $134.69 | $2,020 |
| A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 14 | 11 | $169.34 | $2,371 |
By year: 2022 $37K for 11,263 services; 2023 $42K for 2,619 services; 2024 $49K for 3,029 services.
Medicare prescription drug claims, 2024
In 2024, the drug Maria A Scouros prescribed most often to Medicare patients was Anastrozole, with 260 prescriptions and refills. In total Maria A Scouros wrote 1,923 Medicare prescriptions that cost $8.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 260 | 751 | 78 | $3,829 |
| Keytruda Pembrolizumab | 126 | 126 | 15 | $1.3M |
| Dexamethasone Generic | 118 | 118 | 29 | $898 |
| Xtandi Enzalutamide | 62 | 62 | Under 11 | $811K |
| Alendronate Sodium Generic | 52 | 148 | 20 | $301 |
| Imatinib Mesylate Generic | 50 | 50 | Under 11 | $7,691 |
| Truxima Rituximab-Abbs | 49 | 49 | Under 11 | $348K |
| Herceptin Trastuzumab | 49 | 49 | Under 11 | $216K |
| Hydroxyurea Generic | 49 | 139 | 13 | $1,220 |
| Ondansetron Hcl Generic | 48 | 48 | 22 | $837 |
| Bortezomib Generic | 45 | 45 | Under 11 | $19K |
| Opdivo Nivolumab | 44 | 44 | Under 11 | $610K |
| Verzenio Abemaciclib | 36 | 36 | Under 11 | $510K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 35 | 45 | Under 11 | $56.16 |
| Calquence Acalabrutinib Maleate | 35 | 35 | Under 11 | $520K |
Brand drugs: 785 claims; generic drugs: 1,138 claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Maria A Scouros $1,491 ($1,491 in general payments such as food, travel and fees) from 21 companies. The largest payer was Pfizer Inc. with $195.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 7 | $195 |
| Sobi, Inc SOBI.ST | 6 | $154 |
| Merck Sharp & Dohme LLC MRK | 6 | $152 |
| Telix Pharmaceuticals TLX | 1 | $136 |
| Progenics Pharmaceuticals, Inc. | 1 | $125 |
| Astellas Pharma US Inc 4503.T | 4 | $92.47 |
| Dendreon Pharmaceuticals LLC | 3 | $89.9 |
| Eisai Inc. 4523.T | 3 | $84.27 |
| Celgene Corporation BMY | 4 | $82.36 |
| Kite Pharma, Inc. GILD | 2 | $54.68 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.